So basically the O/S will be roughly 64 million(as of today) with the A/S at 186 million with a pps anywhere between .25 to .30 (as of today). You got to think the pps will go up prior to the vote with a smaller split(may settle at .003-.0035). That leaves Matt just under $56 million in funds if he dilutes to the max. Thats a far cry from the $180 million in funds in the 500/1 split. Either one of two things has occurred. Matt feels he can get it done with lesser funds combined with revenues that will transpire starting this year,or he found a serious investor. Maybe Matt had a talk with BCBS and convinced them to lessen the split to a assure a passing vote(probably makes no difference in which way we vote) while they open their wallet a little bit. Which ever way you shake it,this sector is guaranteed and CBAI is positioned for greatness,otherwise no way they lower the split.

OOOPS..Sorry

Great news for sure. One thing i don't get though..


“The number of authorized shares of Capital Stock of the Company shall be 255,000,000 shares, of which 5,000,000 shares shall be Preferred Stock, having a par value $0.0001 per share, and 250,000,000 shares shall be Common Stock, having a par value $0.0001 per share.”

As of today the O/S is roughly 6.4 billion. A 100/1 would take it to 640 million. The above statements math equates to 510 million. Where is the other 130 million shares? Maybe i'm doing something wrong here. Could CBAI be retiring the remainder?

Thanks for the update. Always appreciated.

Stems alone probably cost roughly 600k. Lab equipment is unsure. Lets round of this acquisition at $1mil. Probably used the remaining 500mil shares in the AS at .002,which equates to $1mil. Its anybody's guess right now.

Well there is one thing we can officially put to rest is the value of discarded stems. This theory was previously kept quite,but i think it is now evident in the form of an official PR. Why take on an extra 1400 stems(which probably cost us $300 each = $420,000)if we were only interested in the annually defined 600 stems and the lab equipment? No current addition in revenues created by purchasing these 1400 discards. So then why not toss the 1400 discards away?

A Brighter Decade Ahead for Biotech..

Investors from around the world are invited to view fundamental and technical analysis at www.WorldStreetFundamentals.com.

With the announcement of Pfizer's Sandwich facility planning on closing its doors, attention to the biotech sector has been raised- along with many eyebrows. There is quite a bit of speculation for the sector to be well on its way with new markets emerging through 2015, money managers and sector analysts alike see great opportunity about.

Biotech is enabling creation of new drugs at a faster pace than the traditional pharmaceutical model and some believe that after a decade of mediocre performance it is approaching an inflection point. Companies are much more conducive to focusing on productivity and the sector is showing signs of being back to top growth by 2013 due to the opportunity emerging markets have created.

I'm not a fan of the R/S either. Is it not possible that there just isn't enough time to wait for two profitable quarters before the split? This sector is not a gradual moving one like most,and can accelerate rapidly at any given time. Pretty hard to predict and set a longer plan in motion when its so unpredictable. CBAI needs to position itself now. Yeah it doesn't absorb to well currently,but it may be necessary for future positioning. I really don't get what people expect. What did CBAI start with? Not much. As we may be in not a favorable pps position,the company itself has come a long way to be positioned where it is now. I guess most would have preferred a smaller scaled company that would of had a moderate gains(maybe to .03)and then eventually get swallowed in the avalanche that is soon to come. Don't get me wrong those are some decent gains,but will pale in comparison to where this can go.

"A SMALLER reverse and a SMALLER increase in AS could achieve the same outcome, WITHOUT killing the current shareholder".

There is no way of knowing this for sure. What if the $170mil(approx)that will be available after the split isn't already accounted for? What if the acquisitions made after the split are slam dunks,but upwards of $150mil is needed? We just do not know what the blue print is,yet.

In all fairness Dianne,you are speaking of this company as if its market is already in place. The annuity model imo is not the bread winner here. Matt already stated discarded stems are worth much more. Something is getting really close to happening. How many discards can we extract from the donated placenta contracts we have in place? I'd say a heck of a lot. We have labs in four continents and Blue Cross is heavily involved.

I think the stem cell arena is going to explode in the next few years and companies are positioning themselves accordingly. I also think CBAI is really close with all the tools in place but needs to get over this financially recognizable hump. Matt obviously realizes this and is pushing for position NOW before we miss the boat. In all seriousness,who in the medical arena is going to take a sub penny(OTCCB)company seriously(especially investors)? CBAI needs off this exchange now,combined with the right type of acquisitions after the split will send this company to heights never dreamed.

Matt knows it and more importantly so does BCBS. This was the plan all along.

Have a good time Agent. Let us know how the tour went.

P.S..Try and pry a little info out Matty,would ya?

Locks,thanks for attending. We are anxiously awaiting any updates you can provide. Get that laptop warmed up.

Dianne with all due respect..You are not trying to make a big deal out of a $5500 amount owing in 2008,are you?

Well i guess my numbers were a bit off,but it would be a little more assuring if Matt had a higher stake in this.

The writing was on the wall when Matt sold the majority of his shares last summer for apparent personal reasons. He knew then he was going to initiate this 500/1 split,that is why he sold then. I think there would of been some legal involvement initiated by some investor(s) if he recently sold prior to the R/S announcement. I guess the Schissler's combined income of 400k doesn't crack it.

I'll support a 100/1 split and re-authorize another 80mil,giving us a total of 150mil after the A/S are diluted. At current levels that will give Matt another $120mil to go out and do his thing. With that kind of money,Matt should be able to get us to the magical $2/share on performance alone while maintaining a more deserving current shareholder value.

Locks..Question..How old is this video from Cyro-Cell?

http://cryocell.org/

Funny on how they have a $50,000 insurance blanket for customers that don't get fulfilled when their sample needs to be used. Isn't that the same coverage CBAI has? Just curious.

Thanks Locks.

Nice to see some real photos from inside Cyro-Cell. Nice looking facility..

http://www.facebook.com/CryoCellMexico#!/photo.php?fbid=10150396917355457&set=a.10150182546475457.413083.244514110456&theater

http://www.facebook.com/CryoCellMexico#!/photo.php?fbid=10150398520520457&set=a.10150182546475457.413083.244514110456&theater

Question..Mr.Long..You have stated that the placenta from a private contract is most likely then donated to CBAI. My question is how many more viable stems could there be left over after the initial extraction?

"An acquired stem through default is not a contracted stem either. It is a Discarded stem purchased at auction without a contract".

Are you sure about that? From what i know the acquiring company assumes the contract as well.

Not sure if this was discussed,but Mr.Long's theory that CBAI is sitting on a boat load of defaulted stems can be tossed out the window.It appears that Matt is not interested in private defaults,as stated below. Public donated stems is the way to go it seems.Will Matt buy a majority interest in VIDAPLUS,who must hold a ton of donated stems since they have been collecting since 1996,post R/S? If you ask me,Matt needs the cash to buy up as much sellable stems he can get his hands on.As he states,"he who controls the inventory,controls the sector".

Matt Schissler
Norman:
We haven't sold default contracts. Less than 1% of our contracts default. Even then it makes no sense to sell. it costs very little to keep them stored. An example is a family hadn't paid us for seven years. Bad contract right? ... Should dispose of it. BUT, that family moved to Japan, and because our bill was a once a year bill, it got lost in the move, forgotten about. That family called us a few months ago. Their daughter has a rare form of cancer and needs her stem cells. We had them stored. They paid their seven years and we shipped them the sample. Our default contracts cost us about $1500 bucks a year in total cost, yep, thats it. not per sample, in TOTAL. Sure, we can make a few dollars selling them, but it only takes one story like the family in Japan not having their stem cells, to bring the whole house down. If the default rate ever got too expensive, we would sell them off, but right now, its just not worth it.

Interesting to see VFIN sitting at .004.

Like i said on Friday,if this thing settles and holds back at .004(or better),it would be smart to hold and wait. There is no way the pps should get back to where it was after a R/S announcement unless there is something cooking.

Not necessarily. If Matt puts the company in a highly profitable position,a buy back could then be afforded. If he has any scruples,that is what he'll do.

Matt is looking for inventory. Period.

Wondering what Vidaplus has in inventory numbers. They have been publicly collecting since 1996. Must be a boat load of publicly donated stems over there. Research stems inventory for CBAI within a year? Could taking over this company involve the R/S? I think so and Matt probably has the sale of these stems pretty well lined up.

Nice move. Europe is where its at. Maybe Mr.Longs theory will be executed in Europe,not the U.S.

"Although Vidapluscm began operations in 2008, the laboratory has operated as a public cord blood bank since 1996. All cord blood collections go through the same level of quality control required for public donations of cord blood".

NEWS..

Cord Blood America Announces Purchase of Minority Interest in Spanish Stem Cell Storage Company

LAS VEGAS, Feb. 14, 2011 /PRNewswire via COMTEX/ -- Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that it has purchased a minority interest in Stem Cells VIDAPLUS, a Spanish-owned company which preserves umbilical cord stem cells at the Institute of Transfusion Medicine and Immunology of the Red Cross in Frankfurt, Germany.

"Headquartered in Madrid and founded in 2007, VIDAPLUS (www.vidapluscm.com) is one of the premier stem cell storage companies in Europe. The Spanish economy is rebounding and we believe this investment both gives Cord Blood America an increased presence in Europe and diversifies our revenue stream," said Matthew Schissler, Cord Blood America CEO and co-founder.

"The investment is organized in tranches that allows Cord Blood America to increase its stake in the Company over time including, eventually, taking a controlling interest," Mr. Schissler said. Cord Blood America previously announced it acquired 51 percent of stellacure GmbH in Germany, which also operates in conjunction with the German Red Cross.

About Cord Blood America

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.

Safe Harbor: This press release contains forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned that such forward looking statements should not be construed as a guarantee or assurance of future performance or results. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained herein will in fact occur. These forward-looking statements are based on current expectations, and the Company assumes no obligation to update this information. Readers are urged to carefully review and consider the various disclosures made by the Company in its Form 10-K and in the Company's other reports filed with the Securities and Exchange Commission that discuss certain of the risks and factors that may affect the Company and its business.

CONTACT: Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com

All in all not a bad day considering. I expected much worse than a 20% hit. Today's trading has showed me there is serious value in this company and something big is in the works down the road. In Matt's video today what was his number four reason for SS? To be positioned to make a LARGE purchase. I can understand the people who bought in the .0021-.0025 bottom feeding zone,looking to make a quick buck on a small rise. The buying that went on towards the latter part of the day(.0028-.0032)indicates value. We hit a daily low of .0021 on a day when a R/S split has been announced and there was still all that buying in this range(.0028-.0032)? Lets see what next week brings. I still stand on the fact that if the pps settles at or near .004,the R/S is part of a huge master plan.

Question for everyone. Which scenario is most likely..

1. At our current SS getting to a .10 pps.........or

2. With a new SS and starting pps of $2 or so with an uplist(AMEX) which will provide exposure and get to $50 pps.

I'll take number 2. Look,we all new what we were getting into when we bought into this. A company with good strategic positioning that carries debt. How else was Matt suppose to position us where we are today? We were ok with the massive dilution as long as it got us into the game. Well guess what,its time to play. Debt is almost gone and not significant and we are partnered with many companies and institutions to take us to the next level. Everything is in place(lab and all). Isn't this what we were waiting for all along? A share buyback would of been sweet but from a sub penny company? C'mon people.

Its time to man up and give this thing a shot. What choice do we have(if you still believe in this sector)? The stem cell sector is going to explode and there is nothing nobody can do to stop it. Science waits for nobody. With the current SS we are going no where.

The question is how many more authorized shares will be infused after the split? O/S will be 11.4 million after the split. What is our current market cap? $25-30mil? Numbers alone puts the pps in $2.20-$2.60 range. In todays SS the pps should be sitting at .0044 based on a $25mil market cap. I agree with Matt when he says its difficult for a company to show its true colors in pennyland.

The big question is,how many more AS after the split and what are they to be used for? If its for a major acquisition or merger that will sky rocket our market cap instantly combined with major growth potential in this fast growing sector,then why not?

Like i stated earlier. If the pps settles back in the .004 range, then there is something bigger than meets the eye with this R/S. Most of the selling today is purely based on emotion,combined with the negative impact a R/S NORMALLY has. This doesn't mean CBAI is tanked. Many companies have flourished post R/S. I'm waiting to see where the pps settles in the next week or two,coupled with some more info.

Same here.Holding and a "NO" vote.

IMO if the pps holds where it is(even after a week or so),then the R/S is part of the bigger picture. If the pps drops and then levels off at something significantly lower than the current pps,well..........

Tomorrow(or next few days) we find out who is holding the cards here. The pps should take a hit,but if it quickly levels back to .004 then there is a whole lot more happening here.

I hope so. Matt is usually good for following up on something initially negative.

Load the boat when this(if) drops in the low 3's or 2's.

I don't see it either. I guess Matt is looking at CBAI funding themselves after the Mexico deal while turning profitable. A pps of $2.00(at current levels) while being profitable looks much more attractive i guess. Isn't the minimum pps $2 to get on the AMEX?

What percentage of our discarded stems did Fisher BioSciences receive at the time of the CorCell purchase?

Well,i've just been knocked over with a feather.